Inovio to present at upcoming scientific conferences

Plymouth meeting, pa. , oct. 1, 2024 /prnewswire/ -- inovio (nasdaq:ino), a biotechnology company focused on developing and commercializing dna medicines to help treat and protect people from hpv-related diseases, cancer, and infectious diseases, today announced that it will present at the following scientific conferences: aacr special conference in cancer research: tumor immunology and immunotherapy poster by dr. matthew morrow, vp of translational sciences at inovio abstract title: reduction in surgical interventions for the treatment of recurrent respiratory papillomatosis by ino-3107 is associated with enriched macrophage, dendritic cell and t cell signatures in patient airways date and time: october 19, 2024, 6:00 - 8:15pm et location: boston, ma isv congress 2024 oral presentation and poster by dr. michael sumner, chief medical officer at inovioabstract title: clinical assessment of adjuvant immunotherapy, ino-3107, in adult patients with recurrent respiratory papillomatosis (rrp) date and time: october 22, 2024, 4:20pm kstlocation: seoul, korea fall voice poster by dr. jeffrey skolnik, svp of clinical development at inovioabstract title: clinical assessment of adjuvant immunotherapy, ino-3107, in adult patients with recurrent respiratory papillomatosis (rrp) date and time: october 25 – october 26, 2024 location: phoenix, az world vaccine congress europe presentation and panel discussion by dr. dave liebowitz, svp early-stage clinical development at inoviotrack: pre-congress workshop on platform technologiesdate and time: october 28, 2024, 10:00am cet location: barcelona, spain abstracts from these conferences will be made available on inovio's website following each presentation.
INO Ratings Summary
INO Quant Ranking